Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
NCT05006794 · Gilead Sciences · PHASE1 · terminated · last registry update 2026-07-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision to terminate” | – | Registry record, Gilead Sciences |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TACSTD2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-01Results posted on the registry: EMD Serono Research & Development Institute, Inc., Avelumab + Sacituzumab Govitecan (SG) (NCT05327530)
- 2026-08-03Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Enfortumab Vedotin (NCT03869190)
- 2026-08-03Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Enfortumab Vedotin (NCT03869190)
- 2026-07-22Phase 3 first posted: AstraZeneca, Dato-DXd + Rilvegostomig (NCT07720284)
- 2026-06-09Also stopped (terminated): Regeneron Pharmaceuticals, vidutolimod + cemiplimab (NCT04916002)
- 2026-06-02Results posted on the registry: Gilead Sciences, Sacituzumab Govitecan-hziy + Paclitaxel (NCT04527991)
- 2026-05-12Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Cobimetinib (NCT03337698)
- 2026-05-12Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Cobimetinib (NCT03337698)
- 2026-05-01Also stopped (withdrawn): MedSIR, Zimberelimab (AB122) + Domvanalimab (DOM) (NCT07134556)
- 2026-04-28Also stopped (withdrawn): National Cancer Institute (NCI), Tarlatamab + Sacituzumab Govitecan (NCT07328490)
- 2026-04-27Results posted on the registry: University of Washington, Sacituzumab Govitecan (NCT05581589)
- 2026-04-27Also stopped (terminated): University of Washington, Sacituzumab Govitecan (NCT05581589)
- 2026-04-16Phase 3 first posted: Jiangsu Alphamab Biopharmaceuticals Co., Ltd, JSKN016 Injection + Eribulin Mcsilate Injection (NCT07533123)
- 2026-03-10Phase 3 first posted: MediLink Therapeutics (Suzhou) Co., Ltd., YL202 + Eribulin (NCT07461454)
- 2026-02-04Results posted on the registry: AstraZeneca, Dato-DXd + Capecitabine (NCT05104866)
- 2026-02-02Results posted on the registry: AstraZeneca, Durvalumab + Capivasertib (NCT03742102)
- 2026-01-30Results posted on the registry: Gilead Sciences, Sacituzumab Govitecan-hziy (NCT03964727)
- 2026-01-28Phase 3 first posted: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Chemotherapy/ADC Regimen + Fluorizoparib (NCT07371910)
- 2026-01-21Results posted on the registry: National Cancer Institute (NCI), Sacituzumab Govitecan + Loperamide (NCT06865677)
- 2026-01-21Also stopped (terminated): National Cancer Institute (NCI), Sacituzumab Govitecan + Loperamide (NCT06865677)
- 2025-12-18Phase 3 first posted: AstraZeneca, Datopotamab deruxtecan (Dato-DXd) + Docetaxel (NCT07291037)
- 2025-12-05Results posted on the registry: Regeneron Pharmaceuticals, vidutolimod + cemiplimab (NCT04916002)
- 2025-11-04Also stopped (terminated): Gilead Sciences, Magrolimab + Nab-Paclitaxel (NCT04958785)
- 2025-10-03Results posted on the registry: Gilead Sciences, Magrolimab + Nab-Paclitaxel (NCT04958785)
- 2025-09-30Results posted on the registry: Gilead Sciences, Sacituzumab Govitecan-hiy (NCT04319198)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision